


Healthcare Industry NewsFeed
HSMN NewsFeed - 18 May 2021
Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies
Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies
HSMN NewsFeed - 17 May 2021
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
HSMN NewsFeed - 17 May 2021
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors
HSMN NewsFeed - 14 May 2021
FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz(R) IND for Stroke Treatment
FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz(R) IND for Stroke Treatment
HSMN NewsFeed - 13 May 2021
Healionics Raises $4.7M Equity Round to Support Commercialization of Stargraft Vascular Graft
Healionics Raises $4.7M Equity Round to Support Commercialization of Stargraft Vascular Graft
HSMN NewsFeed - 13 May 2021
MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development
MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development
HSMN NewsFeed - 11 May 2021
FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer
FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer
HSMN NewsFeed - 11 May 2021
Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board
Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board
HSMN NewsFeed - 10 May 2021
Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio
Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio
HSMN NewsFeed - 5 May 2021
Isosceles Pharmaceuticals, Inc. Appoints William D. Humphries as its Chief Executive Officer
Isosceles Pharmaceuticals, Inc. Appoints William D. Humphries as its Chief Executive Officer
